According to a recent meta-analysis of seven trials consisting of ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide), treatment with GLP-1 RA has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with T2D [48]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.